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Previous studies of HIV-1 p55Gag immunization of mice have demonstrated the usefulness of targeting antigens to the cellular
compartment containing the major histocompatibility complex type II (MHC II) complex molecules by use of a DNA antigen
formulation encoding Gag as a chimera with the mouse lysosome-associated membrane protein (mLAMP/gag). In the present
study, we have analyzed the magnitude and breadth of Gag-specific T-lymphocyte and antibody responses elicited in Rhesus
macaques after immunization with DNA encoding a human LAMP/gag (hLAMP/gag) chimera. ELISPOT analyses indicated that
the average Gag-specific IFN-c response elicited by the hLAMP/gag chimera was detectable after only two or three naked DNA
immunizations in all five immunized macaques and reached an average of 1000 spot-forming cells (SFC)/10
6 PBMCs. High IFN-c
ELISPOT responses were detected in CD8
+-depleted cells, indicating that CD4
+ T-cells play a major role in these responses. The
T-cell responses of four of the macaques were also tested by use of ELISPOT to 12 overlapping 15-amino acids (aa) peptide
pools containing ten peptides each, encompassing the complete Gag protein sequence. The two Mamu 08 immunized
macaques responded to eight and twelve of the pools, the Mamu B01 to six, and the other macaque to five pools indicating
that the hLAMP/gag DNA antigen formulation elicits a broad T-cell response against Gag. Additionally, there was a strong HIV-
1-specific IgG response. The IgG antibody titers increased after each DNA injection, indicating a strong amnestic B-cell
response, and were highly elevated in all the macaques after three immunizations. Moreover, the serum of each macaque
recognized 13 of the 49 peptides of a 20-aa peptide library covering the complete Gag amino acid sequence. In addition, HIV-1-
specific IgA antibodies were present in the plasma and external secretions, including nasal washes. These data support the
findings of increased immunogenicity of genetic vaccines encoded as LAMP chimeras, including the response to DNA vaccines
by non-human primates.
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INTRODUCTION
Several human immunodeficiency virus type 1 (HIV-1) antigenic
formulations have been tested in animal models and clinical trials,
but the immunogenicity and protection achieved to date are still
far from the desired goals for an HIV-1 vaccine. While the
correlates of immune protection are still only vaguely defined, it is
now generally recognized that an effective HIV-1 vaccine must
elicit strong T-cell responses as well as neutralizing antibody [1–4].
It has been postulated that the immunogenicity of a protein
antigen can be enhanced by targeting the antigen to the major
histocompatibility complex type II (MHC II) processing compart-
ment of professional antigen-presenting cells (APCs). One of the
approaches is the use of the lysosomal associated membrane
protein–1 (LAMP) as a LAMP/antigen chimera to target
endogenous antigens to the MHC II processing compartment
[5–10]. Many laboratories have reported that LAMP targeting can
greatly enhance the immune responses against a number of
antigens, including HPV-16- E7 and E6 proteins; human
telomerase reverse transcriptase (hTert); West Nile virus preM-E;
the thyroid hormone receptor (TSHR); HIV-1 Gag, Env gp120,
Env gp160, and Nef; human melanosomal antigen (MAGE-3);
dengue 2 preM-E; listeriolysin O; and SARS coronavirus N
protein [11–24].
Several approaches have been used to design DNA vaccines
encoding LAMP/antigen chimeras. One frequently used construct
contains the transmembrane and cytoplasmic (TMCy) domains of
LAMP added to the C-terminus of the protein antigen. More
recently, we have found that some antigens, including HIV-1 Gag,
must be incorporated into the entire LAMP molecule in order to
effect enhanced antigen expression and trafficking to the lysosomal
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teins of West Nile, dengue, SARS CoV, HPV and HIV-1, have
been shown to co-localize in vitro with MHC II, LAMP-1, LAMP-
2, and H-2M in multiple cell types by confocal imunofluorescense
microscopy, and/or by immunogold electron microscopy [11–
16,24].
The immunological benefits of LAMP-targeted antigens have
been demonstrated in several mouse strains and, most importantly,
also in humans [25–26]. LAMP/antigen chimeras have been
shown to induce increased CD4
+ responses to the antigens in
several assay systems, producing increased secretion of IL-2, IL-4,
IL-5 and IFN-c cytokines; increased proliferative responses;
a greater number of spot-forming cells (SFCs) in ELISPOT
assays; intracellular cytokine staining (ICS); higher precursor
frequencies; increased functional avidity and a broader response
repertoire [11–24].
The increased CD4
+-mediated responses produced by the
LAMP/chimeras are thought to play an important role in
modulating B-cell, CD8
+ responses and the development of
immune memory [11–24]. When compared to the non-targeted
molecules, LAMP/antigens elicited greatly increased antibody
titers, viral neutralization, antibody affinity and numbers of B-cell
epitopes recognized. CD8
+ responses were also enhanced in
several LAMP/antigen chimeric systems, as assessed by tetramer
staining, IFN-c ELISPOT, chromium release, and the functional
avidities and T-cell response repertoires of CD8
+ cells. The
longevity of the immunological memory of B cells and CD8
+ cells
is also increased in animals immunized with LAMP/chimeras.
Previous studies of HIV-1 DNA antigen formulations have
described an HIV-1 p55gag DNA vaccine that elicited strong,
broad and poly-functional cellular and humoral immune responses
in immunized mice when the Gag sequence was incorporated into
the complete LAMP cDNA sequence and the coding sequences
were bracketed by the inverted terminal repeat (ITR) sequences of
adeno-associated virus (AAV) [14–16]. These observations in mice
led us to investigate the immunogenicity of a naked DNA
encoding the HIV-1 LAMP/gag antigen formulation in Rhesus
macaques, a relevant animal model for testing HIV vaccines for
potential use in humans. We found that immunization of these
primates with a human LAMP/gag (hLAMP/gag) DNA vaccine
promoted a humoral and cellular immune response, which was
associated with a sustained activation of B-lymphocytes as well as
CD4
+ and CD8
+ T cells. Furthermore, Gag-specific T cells were
detected after only two immunizations and were further expanded
by booster injections of hLAMP/gag chimera. These results
substantiate the usefulness of the LAMP vaccination strategy as
a means of effectively eliciting T- and B-cell responses to naked
DNA immunization of Rhesus macaques.
MATERIALS AND METHODS
Plasmids
The mouse LAMP/gag (mLAMP/gag) plasmid was constructed as
described previously [16]: Nucleotides 1–1503 of the HIV-1
HXB2 p55gag gene (GenBank
TM accession number K03455; HIV
sequence database, Los Alamos National Laboratory Theoretical
Biology and Biophysics, Los Alamos, NM, USA) was inserted into
the pITR vector [27], which contains the AAV-ITR flanking the
expression elements (cytomegalovirus promoter and bovine
growth hormone polyadenylation signal). The p55gag sequence
was inserted between the luminal domain and the TMCy domain
of mouse LAMP (mLAMP) (GenBank
TM accession number
J03881), as described previously [16]. In the present study, the
complete mLAMP cDNA described above was replaced by the
human LAMP-1 (hLAMP) cDNA (GenBank
TM accession number
NM005561).
The control plasmids, consisting of mLAMP and hLAMP, were
constructed using the respective complete LAMP sequences
without Gag. The hLAMP/gag plasmid used for vaccination of
Rhesus macaques was produced by Quality Biological Inc.
(Gaithersburg, MD, USA), with a DNA purity of 96% and
endotoxin level of 0.33 EU/mg.
Analysis of protein expression
Human 293 cells were plated in 6-well plates (2610
6 cells/well)
and transfected with plasmid DNA (4 mg) using the FuGENE
TM 6
(Roche Applied Science, Indianapolis, IN, USA) transfection
reagents according to the manufacturer’s instructions. The western
blot analysis was done as previously described [15].
Evaluation of hLAMP/gag targeting by confocal
microscopy
MHC II (I-Ek)-expressing cells (DCEK.ICAM.Hi7, a gift of Dr.
Susan Swain, The Trudeau Institute, Saranac Lake, NY, USA)
[28] were plated onto poly-lysine-coated coverslips in 6-well plates
(2610
6 cells/well) and incubated overnight. The cells were
transfected with the DNA plasmids using Lipofectamine
TM 2000
transfection reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA), and 24–48 h later they were stained to evaluate cellular
localization. Coverslips were fixed in 2% paraformaldehyde in
phosphate-buffered saline (PBS) for 5 min and washed with PBS,
then blocked and permeabilized with PBS containing 4% normal
goat serum and 0.1% saponin. For detection of Gag expression,
the cells were incubated for 1 h with mouse anti-Gag monoclonal
antibody (provided by Dr. James Hildreth, Johns Hopkins School
of Medicine, Baltimore, MD, USA) at a 1:50 dilution. After three
washes with 0.1% saponin in PBS, the cells were incubated for 1 h
with Texas Red-labeled goat anti-mouse IgG (BD Pharmingen,
San Diego, CA, USA) at a 1:500 dilution. Co-localization of the
hLAMP/gag chimera with MHC II of the transfected DCEK cells
was performed by double immunostaining, first for the hLAMP/
gag chimera proteins as described above and followed by anti-
MHC II, by incubating the cells for 1 h with FITC-labeled goat
antimouse I-Ek (14-4-4S) (BD Pharmingen) at a 1:75 dilution. The
cells were then washed three times with PBS, and the coverslips
were mounted onto glass slides using ProLong Antifade reagent
(Molecular Probes, Eugene, OR, USA). Confocal microscopy was
performed using a Wallac confocal laser scanning microscope. Co-
localization of the proteins with MHC II was thus determined by
merging fluorophore images individually captured and digitally
colored by use of Adobe Photoshop 7.0 (Adobe System Corp., San
Jose, CA, USA).
Studies with Mice
Immunization of mice Female BALB/c mice, 6–8 weeks of
age, were obtained from Charles River (Kingston, NY, USA).
Mice in groups of eight were each immunized twice (21 days
apart), intramuscularly (i.m.), with 50 mg of the indicated plasmid
and sacrificed 7 days later. For CD8
+ experiments, the mice were
challenged 21 days after the first immunization with a VDK-1
vaccinia virus plasmid containing the native Gag sequence (10
7
plaque-forming units; NIH AIDS Research and Reference
Reagent Program, Rockville, MD, USA).
Antibody responses Mouse serum was obtained from the tail
vein 7 days after the second immunization. Serum IgG levels were
measured by enzyme-linked immunosorbent assay (ELISA) as
described previously [16].
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mediated immune responses of immunized mice Single-
cell suspensions depleted of red blood cells were prepared from
freshly isolated mouse splenocytes in culture medium (RPMI
medium 1640 supplemented with 5% v/v FBS, 100 U/ml
penicillin/streptomycin, 2 mM glutamine, 50 mM2 -
mercaptoethanol, and 0.01 M HEPES buffer). Splenocytes were
counted and resuspended at 10610
6 cells/ml in culture medium
for T cell-mediated assays. T-cell responses of immunized mice
were measured as described previously [15].
Studies with Rhesus macaques
Rhesus macaques Five healthy 4- to 8-kg male Rhesus
macaques were maintained in the non-human primate facility of
Southern Research Institute, Frederick, MD, USA. Animal care
and treatment were in accordance with standards approved by the
Institutional Animal Care and Use Committee, according to the
principles set forth in the Guide for the Care and Use of
Laboratory Animals, National Research Council, National
Academy Press, 1996.
Immunization of macaques Each animal was immunized
intramuscularly (i.m.) five times at weeks 0, 4, 14, 22 and 38 with
5 mg of hLAMP/gag DNA plasmid using a biojector, and 18 blood
samples were drawn over the 42 week experiment period. Mucosal
samples including mouth swabs, nasal and rectal washes were
collected after four DNA immunizations. Blood and mucosal
samples of non-immunized macaques were supplied periodically
as controls.
Isolation of peripheral blood mononuclear cells
(PBMCs) PBMCs were isolated by centrifugation (4006g,
40 min) on a Ficoll-Hypaque gradient (Amersham Biosciences
Piscataway, NJ, USA). Mononuclear cells were collected from the
interface and washed three times in cold phosphate-buffered saline
with Ca2
+ and Mg2
+ (GIBCO, Grand Island, NY, USA). Residual
red blood cells were removed with ACK lysing buffer (Quality
Biological Inc., Gaithersburg, MD, USA). PBMCs to be used for
cytokine analysis or ELISPOT assay were resuspended in
supplemented culture medium (RPMI 1640 medium containing
1% FBS, 100 U/ml penicillin/streptomycin, and 2 mM L-
glutamine).
CD8
+ lymphocyte separation Positive selection of cells
expressing CD8
+ antigen was performed with monoclonal anti-
human CD8
+ conjugated to R-phycoerythrin (PE) and microbeads
conjugated to monoclonal anti-PE antibodies (CD8 MicroBead
kit, Miltenyi Biotec, Bergisch Gladbach, Germany) as described by
the manufacturer. The CD8
+ cells were .98% pure as assessed by
flow cytometry. Fractionated cells were suspended in RPMI-10
medium and used on the same day for ELISPOT assay.
HIV Gag-specific IFN-c ELISPOT assay The frequency of
IFN-c-producing CD4
+ or CD8
+ T cells from immunized Rhesus
macaques was measured by ELISPOT assays, using the IFN-c
ELISPOT set from BD-Biosciences Pharmingen according to the
manufacturer’s protocol. Initially, ELISPOT plates were coated
with anti-human IFN-c Ig at 5 mg/ml and incubated at 4uC
overnight. After blocking with RPMI-1640 containing 10% FBS
for 2 h at room temperature (RT), total PBMCs (3610
5 cells/well)
were cultured with hybridoma serum-free medium (GIBCO)
supplemented with 1% FBS, 100 U/ml penicillin/streptomycin
and 2 mM L- glutamine, in the presence of 10 mg/ml of HIVSF2
p55 gag recombinant protein (rGag); or HIV gag 15-amino acids
(aa) peptides overlapping by 11-aa; or 20-aa overlapping by 10-aa.
A negative control included in each assay consisted of medium
lacking HIV antigen. Phytohemagglutinin (PHA) (Sigma, St.
Louis, MO, USA) at 5 ng/ml with 500 ng/ml ionomycin (Sigma)
was included as a positive control for each Rhesus macaque. After
16 h of culture, the plates were washed and incubated with
biotinylated anti-human IFN-c for 2 h at RT, followed by HRP-
conjugated avidin for 1 h at RT. The reaction was developed with
3-amino-9-ethylcarbozole substrate (Calbiochem-Novabiochem
Corporation, San Diego, CA, USA). Analysis of the IFN-c levels
was performed using an immunospot image analyzer (Cellular
Technology Limited, Cleveland, OH, USA). Background spots
obtained with medium alone were subtracted from each
experimental value. All results were expressed as mean number
of SFC per 10
6 PBMCs. For each antigen, a responder Rhesus
macaque was defined as one exhibiting a significant number IFN-c
SFC cells over the background value or value for non-immunized
macaques, at any time point over the immunization course.
Analysis of IL-6 secretion by capture ELISA Total PBMCs
(5610
5 cells) from immunized macaques were cultured in a 96-
well plate (Nunc, Roskilde, Denmark) containing recombinant
human IL-2 (500 U/well). Except for the negative and positive
Figure 1. Expression and trafficking of mouse and human LAMP/gag.
(A) Western blot analysis of human 293 cells transfected with mLAMP/
gag and hLAMP/gag plasmids. Samples were probed with an anti-Gag
monoclonal antibody. The molecular weight markers are indicated on
the right.
(B) DCEK cells were transfected with the hLAMP/gag plasmid and
stained with anti-Gag (red) or anti-MHC II (green) monoclonal
antibodies. Digitally merged image shows co-localization of the
hLAMP/gag chimera- and MHC II-containing compartments (yellow).
doi:10.1371/journal.pone.0000135.g001
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(Sigma) containing 500 ng/ml ionomycin, respectively, PBMCs
were stimulated with 10 mg/ml HIVSF2 p55 rGag. After a 48-h
incubation at 37uCi n5 %C O 2, the supernatants were collected
for detection of secreted cytokines and stored at 220uC until
further use. IL-6 concentrations were determined using a monkey
IL-6 OptEIA
TM set (BD Pharmingen).
HIV Gag-specific humoral and mucosal immune
responses Serum samples were tested throughout the
experimental period for the presence of binding antibody to
HIV Gag. Nunc plates were coated with 5 mg/ml HIVIIIB lysate
in sodium carbonate-bicarbonate buffer, pH 9.4 (Pierce, Rockford,
IL, USA). After overnight incubation at 4uC, the solution was
removed, and the plates were washed six times with PBS
containing 0.05% Tween-20 (PBS-T) wash buffer. The plates
were then incubated for 2 h at 37uC with blocking buffer (PBS-T
with 5% FBS) and then washed three times with PBS-T. IgG
responses were measured with four serial 1:3 dilutions, starting at
1:100, in blocking buffer. IgA responses in serum, nasal, mouth
and rectal washes were measured with 100 ml of 10-fold diluted
sample added to the blocked plate in duplicate. The plates were
incubated overnight at 4uC. After six washes, 100 mlo f
horseradish peroxidase-conjugated rabbit anti-monkey IgG
(Sigma) diluted 1:5000 in blocking buffer was added to each
well. For the detection of IgA antibodies, 100 ml of goat anti-
monkey IgA (Nordic Immunology, Tilburg, Netherlands) diluted
1:5000 in blocking buffer was added to each well. The plates were
incubated for 2 h at 37uC and washed eight times with washing
Figure 2. Immune responses in mice.
Mice were injected i.m. on days 1 and 21 with 50 mg of the indicated pITR plasmids encoding mouse or human LAMP or LAMP/gag chimeras.
(A) Humoral responses. Blood samples were collected 7 days after the second immunization. Each titration curve indicates the OD450 of Gag-specific
total IgG present in serial dilutions of pooled serum from individual groups of mice.
(B) CD4
+ immune responses. CD4
+ IFN-c
+ secretion from splenocytes of mice injected twice with the indicated plasmids. Animals were sacrificed on
day 28, and splenocytes were prepared for assay of CD4
+ T-cell responses and incubated in the presence or absence of antigen. A representative
experiment is shown. Data are Mean6SD after subtraction of the background control values.
(C) CD8
+ immune responses. On day 21, mice were injected i.p. with 10
7 PFU of rVV-gag-pol. Five days later, 10 mg of the H-2Kd-binding HIV-1 Gag
peptide was injected i.v., and splenocytes were harvested after 2 h and analyzed ex vivo. Gag-specific CD8
+ T-lymphocytes producing IFN-c was
quantified by flow cytometry and tetramer binding in the CD8
+ splenic population. Cytolytic activity was also analyzed in a 4-h
51Cr release assay
using P815 target cells pulsed with the H-2Kd-binding HIV-1 Gag peptide. The effector cells from the various groups of immunized mice were used as
indicated. Nonspecific lysis (using unpulsed P815 target cells) was ,5% for all groups (not shown). A representative experiment is shown.
doi:10.1371/journal.pone.0000135.g002
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added to each well and incubated for 15 min at RT. The reaction
was stopped by adding 100 ml of 1 M sulfuric acid, and
absorbance at 450 nm was measured in a BIO-RAD model
3550 microplate reader.
B-cell epitope mapping HIV-1 Gag 20-aa peptides,
spanning residues 1 to 490 with a 10-aa overlap (NIH AIDS
Research and Reference Reagent Program), were diluted in 0.1 M
sodium carbonate-bicarbonate buffer, pH 9.4, to give a con-
centration of 5 mg/ml, and 50 ml of the individual peptide was
added to each well of a 96-well plate, in duplicate. After overnight
incubation at 4uC, the solution was removed, and the plates were
washed six times with PBS-T. They were then incubated with
blocking buffer for 2 h at 37uC and washed three times. Serum
samples (100 ml of a 1:300 dilution in blocking buffer) were added
to each well, and the plates were incubated overnight at 4uC. After
the plates were washed six times, 100 ml of HRP-conjugated rabbit
anti-monkey IgG (Sigma), diluted 1:5000 in blocking buffer, was
added to each well. The plates were incubated for 2 h at 37uC and
then washed. Turbo TMB substrate solution (BD Pharmingen)
was added to each well and incubated for 15 min at RT. The
reaction was stopped by adding 100 ml of 1 M sulfuric acid, and
absorbance at 450 nm was measured in a BIO-RAD model 3550
microplate reader.
Statistical Analyses All the graphs were made using
GraphPad Prism Version 4.0a for Macintosh (GraphPad
software, San Diego, CA, USA).
RESULTS
Comparison of hLAMP/gag and mLAMP/gag: Gag
Expression and Cellular Trafficking in Transfected
Cells
LAMP/Gag expression and cellular trafficking to the cellular
MHC II compartment has been repeatedly demonstrated in
studies with murine LAMP chimeras [11–16]. The present study
confirmed the similar expression and trafficking of the human
LAMP/Gag protein chimera. Western blotting with anti-Gag
antibody showed the presence of ,200 kDa LAMP/Gag protein
at comparable levels in 293 cells transfected with either mouse or
human LAMP/gag (Figure 1A). There appeared to be increased
degradation of Gag in the hLAMP/gag transfected cells; however,
the significance of this is not known as the results of other similar
studies of mLAMP/gag transfected cells have shown variable levels
of Gag degradation products [14–16]. Co-localization of the
hLAMP/gag chimera transgene product with the cellular MHC II
was confirmed with transfected DCEK cells stained with anti-Gag
and anti-MHC II monoclonal antibodies (Figure 1B).
Figure 3. Protocol for immunization of Rhesus macaques with the
hLAMP/gag plasmid.
Immunization and blood sample collection from five Rhesus macaques
immunized five times with 5 mg of hLAMP/gag DNA plasmid were
carried out as shown.
doi:10.1371/journal.pone.0000135.g003
Figure 4. T-cell immune response of immunized macaques.
IFN-c ELISPOT assays were performed with PBMC samples from each of
five Rhesus macaques immunized with 5 mg of hLAMP/gag DNA
plasmid at weeks 0, 4, 14, 22 and 38. Each time point represents the
average number of cells activated in separate assays by rGag protein or
Gag 15- or 20-aa peptides, performed at two laboratories in duplicate or
triplicate. Each bar is the average number of cells activated in 8 to 20
ELISPOT wells+/2S.D. and represents the number of IFN-c
+ cells per 10
6
PBMCs.
doi:10.1371/journal.pone.0000135.g004
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Verification of the in vivo immune responses to the hLAMP/gag
chimera and a comparison of the responses to mLAMP/gag were
examined with mice immunized on days 1 and 21 with 50 mg
DNA of the pITR plasmid vectors encoding the mLAMP/gag and
hLAMP/gag chimeras. Total anti-Gag IgG responses were assayed
with blood collected on day 28 (Figure 2A). The response of mice
immunized with the hLAMP/gag construct was considerably
greater than the response to the mLAMP/gag.
Splenocytes of mice sacrificed after the two immunizations were
assayed for T-cell IFN-c responses. The MHC II-targeted mouse
and human LAMP/gag plasmids elicited comparable IFN-c
+
responses (8000 pg/ml and 6000 pg/ml, respectively) (Figure 2B).
Assays of CD8
+ T-cell responses were carried out with mice
immunized once with 50 mg of the plasmid DNA, followed 21 days
Figure 5. Comparison of the T-cell responses of immunized
macaques to Gag 15- and 20-aa peptide pools.
Comparison of the average number of IFN-c
+ cells activated by Gag 15-
and 20-aa peptide pools in the ELISPOT assays, using PBMCs from five
individual Rhesus macaques after three DNA immunizations. Each bar
represents the number of IFN-c
+ cells per 10
6 PBMCs.
doi:10.1371/journal.pone.0000135.g005
Figure 6. CD4
+ T-cell immune responses of immunized macaques.
ELISPOT assays show the average number of IFN-c
+ cells activated by
recombinant Gag protein with CD8
+-depleted PBMCs from five
individual rhesus macaques after four DNA immunizations (at week
36). Each bar is the average count from duplicate wells+/2S.D. and
represents the number of IFN-c
+ cells per 10
6 CD8
+-depleted PBMCs.
doi:10.1371/journal.pone.0000135.g006
Figure 7. T-cell immune responses to twelve pools of ten 15-aa Gag
peptides each.
T-cell responses of PBMCs from immunized Rhesus macaques to 12
pools, each consisting of ten gag 15-aa peptides overlapping by 11-aa,
were measured by use of ELISPOT assays at week 20 after three DNA
immunizations. Each bar represents the frequency of IFN-c
+ cells per 10
6
PBMCs.
doi:10.1371/journal.pone.0000135.g007
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tion with recombinant vaccinia-Gag-Pol (rVVGag-Pol). Five days
later, the mice were injected with an immunodominant H-2Kd-
restricted Gag peptide epitope and sacrificed after 2 h for the ex
vivo assay. Mice immunized with both the mouse and human
LAMP/gag chimeras uniformly developed significantly strong
CD8
+ responses as measured by epitope-specific CD8
+ tetramer
binding, intracellular IFN-c staining, and CTL lysis of peptide-
pulsed target cells (Figure 2C). The larger fraction of CD8
+ T cells
expressing IFN-c (.20%) following inoculation with recombinant
vaccinia virus encoding Gag, in comparison with the proportion of
tetramer positive cells, is attributed to the massive in vivo expansion
of Gag-activated CD8
+ T cells reactive against several other
Gag MHC I epitopes, besides the immunodominant H-2Kd-
AMQMLKETI peptide-tetramer epitope complex.
Immunization of Rhesus Macaques with the hLAMP/
gag DNA Plasmid
Five Rhesus macaques were immunized i.m. with 5 mg of the
hLAMP/gag plasmid at weeks 0, 4, 14, 22 and 38, and the cellular
immune responses of each of the individual macaques to the
hLAMP/Gag chimera were measured at 12 time points, through
42 weeks (Figure 3). ELISPOT assays to quantify the IFN-c
+-
secreting cells present in the macaque PBMCs were independently
performed at the Southern Research Center and The Johns
Hopkins University laboratories. Three different forms of the Gag
protein antigen were used to stimulate the PBMCs: HIV rGag and
15- and 20-aa peptide pools that encompass the entire Gag
sequence. PBMCs stimulated with all the three formulations of
Gag antigen presented similar numbers of IFN-c
+ SFCs. These
ELISPOT results are presented as the average of the results
obtained with the three Gag preparations at the two laboratories.
The magnitude of the vaccine-induced T-cell responses varied
from macaque to macaque; however, in every case, IFN-c
secretion was detected after the second immunization at week 8,
reached the highest level of 600 to 1200 SFC/10
6 cells at week 18
following the third immunization, and declined gradually until
further immunizations were given at weeks 22 and 38 (Figure 4).
These studies included an analysis of the relative efficiency of the
15- or 20-aa peptides in stimulating T-cell responses in vitro, and
we observed that PBMCs of all the five immunized macaques
stimulated with the 15- and 20-aa Gag peptide pools separately,
showed no significant difference in the IFN-c response (Figure 5).
CD4
+-specific responses were also studied by ELISPOT analyses
with CD8
+-depleted PBMC stimulated with rGag. All five
macaques showed a response in the range of 200–1000 IFN-c
+
SFC/10
6 CD8
+-depleted cells, indicating a potent CD4
+-mediated
response (Figure 6).
Mapping of Gag T-cell Immunogenic Determinants
The repertoire of peptide-specific responses elicited by lysosomal
targeting in BALB/c mice has been shown to include the same
immunodominant epitopes as those elicited by the native antigen;
however, the chimeric antigen commonly elicits enhanced and
additional T-cell responses that were not detected with the native
antigen [24]. In an analysis of the potential effect of LAMP
targeting on the breadth of the T-cell repertoire in macaques,
PBMCs from the immunized macaques were tested at week 20,
after 3 DNA immunizations, for T-cell responses to 12 different
pools consisting of ten peptides each, of the 15-aa Gag peptide set
(Figure 7). T-cell responses to specific peptides were detected with
each of the four immunized macaques that were included in this
study. Three of the immunized macaques showed responses to five
to eight of the peptide pools. One of the animals, macaque #3162,
showed activation of IFN-c
+ cells in response to all of the peptide
pools. Collectively, these data suggest that hLAMP/gag can prime
a broad T-cell response in primates.
B-cell Responses of Rhesus Macaques to the hLAMP/
gag DNA Plasmid
One remarkable feature of the DNA-encoded LAMP-targeted
antigens has been the dramatic increase in antibody-mediated
responses of immunized mice. Similar findings have been obtained
with the five immunized macaques, each of which showed strong
humoral immune responses (Figure 8). The strength of these
responses by the individual macaques followed the same pattern as
the T-cell responses. High anti-gag IgG antibody titers were
present in serum after immunization with hLAMP/gag, indicating
effective priming. Four of the five vaccinated macaques (#3119,
3162, 3159 and 3117) developed antibodies against HIV-1 after
the second immunization and high antibody titers were achieved
by these four macaques following the third DNA immunization at
Figure 8. Humoral immune responses of immunized macaques.
Gag-specific antibody responses of Rhesus macaques immunized with
hLAMP/gag plasmid were measured by ELISA. (A) Sera diluted 1:100
from individual macaques was assayed for total anti-Gag antibodies
(IgG). (B) End-point titers were measured at week 24 after four DNA
immunizations. The reported titers correspond to the reciprocal of the
highest serum dilution that gave an OD value three times higher than
that of the corresponding dilution of a non-immune serum.
doi:10.1371/journal.pone.0000135.g008
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weakest T-cell response, also elicited a relatively weak antibody
response as compared to the other 4 macaques (Figure 8A). The
third DNA immunization worked as a booster for all the
macaques, and antibody titers reached their highest values after
the 5th injection (at week 38). The end-dilution titers of the IgG
antibodies achieved after four hLAMP/gag immunizations ranged
from 2,700 to 24,300 (Figure 8B).
Serum samples of the immunized macaques were also assayed
for IgA production, Significant levels were detected in three
(#3119, 3159 and 3162) of the immunized macaques (Figure 9A).
IL-6 is a key cytokine for terminal differentiation of B-cells into
IgA-secreting plasma cells in both the mouse and human systems
[29–30]. Interestingly, IL-6 production was seen in the same three
macaques (Figure 9B), correlating with the plasma IgA response.
The presence of Gag-specific IgA in external secretions, including
Figure 9. IgA and IL-6 immune responses of hLAMP/gag immunized macaques.
Gag-specific mucosal immune responses of immunized Rhesus macaques were quantitated by ELISA for IgA and IL-6. (A) Serum IgA levels of the
individual macaques at different time-points. (B) IL-6 production of PBMCs from individual macaques stimulated at week 32 with recombinant Gag
protein after four DNA immunizations.
(C) IgA levels of external secretions of individual macaques.
doi:10.1371/journal.pone.0000135.g009
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immunizations, was also assayed (Figure 9C). The levels of IgA
antibodies detected in mouth swabs and nasal and rectal washes
varied remarkably among the individual macaques; however,
comparatively higher IgA antibodies were found in nasal washes of
all the five macaques.
B-cell Peptide Epitope Mapping
Serum samples collected from the five macaques at week 24, after
four DNA immunizations, were analyzed individually in ELISA
assays against each of the 20-aa Gag peptides, overlapping by
10-aa (Figure 10). The repertoires of peptides recognized by each
of the macaque sera were very similar; all of the animals reacted
with the same 13 of the 49 Gag 20-aa peptides tested. Three
peptides containing B-cell determinants were located at the amino-
terminal, whereas, most of the peptides recognized were located in
the carboxy-terminal region of the Gag protein. These results from
immunized macaques support the conclusion that vaccination with
an hLAMP/gag chimera can prime a broad B-cell response [24].
DISCUSSION
This study demonstrates that Rhesus macaques immunized with
a DNA plasmid vaccine-encoding gag as an hLAMP/gag chimera
develops strong antigen-specific humoral responses as well as
CD4
+ and CD8
+ T-cell responses. Previous studies by others with
candidate DNA vaccines have shown protection of small animals
against pathogenic challenges [31]; however, their performance in
primates has generally been disappointing. Most naked DNA
vaccines have produced sub-optimal immune responses, even with
repeated boosting, with only moderate T-cell responses when
compared to live-attenuated virus or recombinant virus vaccines
and very low or no humoral responses. In contrast, hLAMP/gag
DNA immunization elicited potent CD4
+ T-cell as well as Gag-
specific CD8
+ T-cell responses in macaques after only a few DNA
immunizations. The responses included highly significant IgG
antibody titers after two DNA immunizations in four of the five
immunized macaques and IgA responses in serum and nasal
washes. All of the macaques showed a high IgG antibody titer after
three DNA immunizations, with a rapid and enhanced immune
memory response with the fourth and fifth immunization.
The breadth of the T and B cell repertoire elicited by DNA
HIV vaccines is thought to be important for pathogen control,
perhaps by preventing the selection of escape mutants. We have
previously reported that immunization of BALB/c mice with
LAMP-targeted Gag increases the breadth of B- and T-cell
responses. Moreover, others have shown that human dendritic
cells transfected with LAMP-targeted HIV nef are able to induce
the activation of an increased repertoire of T-cells isolated from
infected patients [26]. In this study, each of the four macaques
tested, produced Gag-specific IFN-c
+ responses to many Gag 15-
aa peptide pools, indicating a broad range of T-cell responses. A
question that remains to be investigated is whether this result
reflects a true increase in the number of new epitopes being
recognized as a result of hLAMP/gag administration or whether
the ability of hLAMP/gag to increase the overall magnitude of the
cellular immune response simply enhances our ability to detect
epitopes that would otherwise have been below the limit of
detection.
We also mapped B-cell epitopes of linear, 20-aa Gag peptides
with serum samples obtained from the macaques after three DNA
immunizations with the hLAMP/gag chimera. The results of these
analyses indicated that some of the peptides behaved as dominant
epitopes and induced strong B-cell activation in all five macaques.
These include two dominant peptides located in the amino-
terminal portion of the molecule, and 10 peptides located in the
Figure 10. Mapping of B-cell epitopes recognized by immunized macaques.
Responses to 49 individual 20-aa Gag peptides overlapping by 10-aa comprising the HIV Gag sequence were measured by ELISA in sera collected at
week 24. The results are shown as the average responses of the five macaques. The antibody activity in each of the five macaques was directed at 13
peptides, with dominant responses to 2 amino-terminal and 10 carboxy-terminal sequences.
doi:10.1371/journal.pone.0000135.g010
Vaccination in Rhesus Macaques
PLoS ONE | www.plosone.org 9 December 2006 | Issue 1 | e135carboxy-terminal portion of the Gag protein. The amino-terminal
region is known for its antigenic properties [32–34] and has been
reported to contain both B and T-cell epitopes and to be relatively
conserved among European HIV-1 isolates [33,35]. The carboxy-
terminal region is also known to bind antibodies developed during
natural HIV-1 infection in humans [36].
Our studies also showed that IgA antibodies were present in the
serum and external secretions of the hLAMP/gag-immunized
macaques. Furthermore, IL-6 production was detected in three of
the five immunized macaques. IL-6 is known to play a key role in
the terminal differentiation of IgA-committing B cells into IgA-
secreting plasma cells in both mice and humans [29–30]. In this
study, the increased production of IL-6 by Gag-specific CD4
+ T
cells is consistent with the induction of HIV-specific IgA B-cell
responses in addition to systemic IgG antibody responses. IgA and
IgG antibodies may function as a first line of defense, preventing
HIV/SIV adherence to the mucosal surface or interfering with
viral replication through secretory IgA [37].
Although T-cell immune responses induced by DNA immuni-
zation are generally moderate, previous studies have demonstrated
that DNA prime is very important in heterologous prime-boost
immunization regimens with viral vectors. The prime-boost
formulations have been shown to induce strong cellular immune
responses and protection in malaria [38–39] and SIVmac [40–41]
models. Moreover, the DNA prime and viral boost approach has
been shown to be important in increasing the breadth of the
response repertoire of viral vector vaccines [42], thereby
contributing to the overall immunological protection. There is
growing consensus that plasmid DNA represents a particularly
good prime immunogen. Therefore, considerable work is now
being done to explore the use of bimodal vaccine regimens in
which the plasmid DNA is used to prime the immune response
and a live recombinant vector is used to boost that immunity [43].
These studies collectively suggest that more work is needed before
a DNA approach alone or a DNA prime followed by a viral vector
boost is able to completely control the pathogenic challenge in
these model systems. A recent report has shown consistent and
strong CTL responses to Gag in macaques immunized with
DNA_CRL 1005-adjuvant Gag plasmids and boosted with rAd5
encoding gag [44]. The studies have established that a significant
percentage of humans respond to both the DNA and adenovirus
approaches, and more evaluation of further potent DNA vaccines
is clearly warranted.
The current study was limited by the small number of animals
and the lack of an HIV challenge system to assess the protective
efficacy afforded by the HIV hLAMP/gag DNA vaccine. A further
goal is to test the effect of LAMP targeting on additional relevant
antigens of the SIV challenge model, in collaboration with the G.
Pavlakis and B. Felber group (Human Retrovirus Section, Basic
Research Laboratory, National Cancer Institute, Frederick, MD,
USA).
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